companies / illexcor-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-12 json
| total_raised | 13,000,00013.0M | D |
|---|---|---|
| founded | null | |
| hq | Henrico, VA | |
| industry | unknown | |
| stage | null |
Oral small-molecule therapy for sickle cell disease
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2026-05-08 | Funding round | 13,000,00013.0M | null | D |
| person | role | src |
|---|---|---|
| Andrew N Fleischman | director | D |
| Andrew N Fleischman | executive | D |
| Giovanni Mariggi | director | D |
| Maneka Mirchandaney | director | D |
| Ted Love | director | D |
| Timothy E Ladin | executive | D |
Apache HTTP Server, jquery 3.6.0, bootstrap 5.3.2, apache
| fact | status | src |
|---|---|---|
| Funding round, $13.0M | sourced | D |
| existence | self-reported | WEB |
| description | self-reported | WEB |
| date | fact | change | src |
|---|---|---|---|
| 2026-09-25latest_round: seed, $13.0M, 2026-05-08 → Funding round, $13.0M, 2026-05-08, D 2026-09-25 | latest_round | seed, $13.0M, 2026-05-08 → Funding round, $13.0M, 2026-05-08 | D 2026-09-25 |
| 2026-09-25provenance_round: attributed → sourced, D 2026-09-25 | provenance_round | attributed → sourced | D 2026-09-25 |
Records begin 2026-09-24. all_changes